Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

107P - Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer


12 May 2023


Poster viewing and lunch


Zhimin Shao


Annals of Oncology (2023) 8 (1suppl_4): 101219-101219. 10.1016/esmoop/esmoop101219


Z. Shao1, Q. Zhang2, N. Liao3, Y. Wang4, H. Li5, Y. Deng6, Y. Lin7, L. Yang8, C. Qian8

Author affiliations

  • 1 Fudan University Shanghai Cancer Center, Shanghai/CN
  • 2 Harbin Medical University Cancer Hospital, Harbin/CN
  • 3 Guangdong General Hospital, Guangzhou/CN
  • 4 Shandong Cancer Hospital, Shandong University, Jinan/CN
  • 5 Peking University Cancer Hospital & Institute, Beijing/CN
  • 6 The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou/CN
  • 7 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN
  • 8 Eli Lilly and Company, Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 107P


Abemaciclib (oral CDK4 and 6 inhibitor) plus endocrine therapy (ET) as adjuvant treatment demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in Chinese patients (pts) with Hormone Receptor (HR+)-positive and human epidermal growth factor 2 (HER2)-negative high risk early breast cancer (EBC). This combination therapy provided sustained clinical benefits at the pre-planned overall survival interim analysis (OS IA2). Here we present the results of the subset of Chinese patients from monarchE at OS IA2.


The overall study design was previously reported. Pts were randomized 1:1 to receive Abemaciclib + ET or ET alone. Eligible pts with ≥4 positive nodes, or 1-3 nodes and Grade 3 disease and/or tumor size ≥5 cm were included in Cohort 1 (C1); pts with 1-3 nodes and central Ki-67 ≥20% who did not meet entry criteria for C1 were included in Cohort 2 (C2). Analyses were conducted in Chinese pts enrolled from Mainland China, Hong Kong, and Taiwan in the intent-to-treat (ITT) population (501 pts), consisting of C1 (440 pts) and C2 (61 pts).


At the time of data cutoff (July 1, 2022), all Chinese pts were off treatment with median follow-up of around 41 months. Sustained benefits of IDFS (HR=0.563, 95%CI: 0.343-0.923) and DRFS (HR=0.586, 95%CI: 0.341-1.006) were observed in Chinese pts in the ITT, with clinically meaningful improvement in the 4-year IDFS rates (88.5% vs 79.6%) and DRFS rates (90.0% vs 82.4%). In C1, the HR for IDFS was 0.582 (95%CI: 0.351-0.965) and DRFS was 0.610 (95%CI: 0.350-1.063), and a consistent benefit of abemaciclib was observed regardless of Ki-67 index. There were limited events of deaths in Chinese pts (abemaciclib plus ET vs ET: 6 [2.3%] vs 5 [2.1%]). No new safety signals were observed in Chinese pts.


Consistent with reported results for the overall ITT population, abemaciclib combined with ET demonstrated clinically meaningful and sustained IDFS and DRFS benefits among Chinese pts with HR+, HER2-, high risk EBC and continued separation of the IDFS and DRFS curves. The OS data remain immature and follow-up is ongoing.

Clinical trial identification


Legal entity responsible for the study

Eli Lilly and Company.


Eli Lilly and Company.


L. Yang, C. Qian: Financial Interests, Personal, Full or part-time Employment: Eli Lilly and Company. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.